Jatkowska Aleksandra, White Bernadette, Gkikas Konstantinos, Seenan John Paul, MacDonald Jonathan, Gerasimidis Konstantinos
Human Nutrition, School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK.
Department of Gastroenterology, Queen Elizabeth University Hospital, Glasgow, UK.
J Crohns Colitis. 2025 May 8;19(5). doi: 10.1093/ecco-jcc/jjae177.
Exclusive enteral nutrition is an established treatment for active Crohn's disease but the role of partial enteral nutrition (PEN) in the broader management of the disease is less clear. This systematic review and meta-analysis reviewed the literature on the role of PEN in Crohn's disease management.
This review was conducted following Cochrane recommendations. The protocol was registered on PROSPERO. Findings were reported following the PRISMA guidelines.
Sixty-four articles were identified, of which 11 reported data from randomized control trials. Good quality evidence suggests that PEN may be used as a maintenance and induction therapy, particularly at high dosages and/or alongside exclusion diets. A higher dosage of PEN is associated with a lower risk of subsequent disease relapse, with benefits observed at intakes above 35% of energy requirements (35%-50% PEN: OR [95% confidence intervals (CI)]: 0.42 [0.27-0.65]; > 50% PEN: OR [95% CI]: 0.27 [0.08-0.88]). Low-quality evidence suggests that postoperative use of PEN may prevent disease recurrence or enhance treatment outcomes when used as adjunct therapy to biologics. PEN can improve nutritional parameters, showing efficacy comparable to EEN in pediatric patients (weight: OR [95% CI]: -0.04 [-0.32, 0.25]). The effect of PEN on improving patients' quality of life is comparable to that of EEN and anti-tumor necrosis factor alpha therapies.
Partial enteral nutrition may help in various aspects of Crohn's disease management but much of the current evidence is of low quality. Well-designed randomized control trials are required to confirm findings from current literature and before clinical recommendations can be made.
全肠内营养是活动性克罗恩病的既定治疗方法,但部分肠内营养(PEN)在该病更广泛管理中的作用尚不清楚。本系统评价和荟萃分析回顾了关于PEN在克罗恩病管理中作用的文献。
本评价按照Cochrane推荐进行。方案在PROSPERO上注册。研究结果按照PRISMA指南报告。
共识别出64篇文章,其中11篇报告了随机对照试验的数据。高质量证据表明,PEN可作为维持和诱导治疗,特别是在高剂量和/或与排除饮食同时使用时。较高剂量的PEN与后续疾病复发风险较低相关,在能量需求摄入量超过35%时观察到益处(35%-50%PEN:比值比[95%置信区间(CI)]:0.42[0.27-0.65];>50%PEN:比值比[95%CI]:0.27[0.08-0.88])。低质量证据表明,术后使用PEN作为生物制剂的辅助治疗可能预防疾病复发或改善治疗效果。PEN可改善营养参数,在儿科患者中显示出与全肠内营养相当的疗效(体重:比值比[95%CI]:-0.04[-0.32,0.25])。PEN对改善患者生活质量的效果与全肠内营养和抗肿瘤坏死因子α治疗相当。
部分肠内营养可能有助于克罗恩病管理的各个方面,但目前的许多证据质量较低。需要设计良好的随机对照试验来证实当前文献中的发现,然后才能提出临床建议。